O
RXDX

OrbiMed’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

OrbiMed’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-250,000
Closed -$9.88M – 169
2021
Q4 		$9.88M Hold
250,000
– – 0.13% 116
2021
Q3 		$5.93M Hold
250,000
– – 0.07% 149
2021
Q2 		$6.14M Hold
250,000
– – 0.06% 143
2021
Q1 		$4.57M Buy
+250,000
New +$5.16M 0.04% 147

Other funds holding RXDX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed's RXDX Position: Q1 2022 in Review

OrbiMed sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q1 2022, closing a stake of 250,000 shares — an estimated $9.88M sold.

OrbiMed first reported a position in RXDX in Q1 2021 and held it in 4 quarters. The position peaked at $9.88M in Q4 2021. 103 funds tracked by Wall St. Rank hold RXDX as of Q1 2022.

  • OrbiMed reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • OrbiMed sold 250,000 Prometheus Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $9.88M.
  • OrbiMed first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • OrbiMed's Prometheus Biosciences, Inc. Common Stock position peaked at $9.88M in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.